AMG-131
Identification
- Generic Name
- AMG-131
- DrugBank Accession Number
- DB05490
- Background
AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and Avandia.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 514.209
Monoisotopic: 511.932273778 - Chemical Formula
- C21H12Cl4N2O3S
- Synonyms
- Not Available
- External IDs
- AMG 131
- AMG-131
- INT-131
- T-0903131
- T131
Pharmacology
- Indication
Investigated for use/treatment in diabetes mellitus type 2.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
T131, an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and Avandia
- Mechanism of action
T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and Avandia
Target Actions Organism APeroxisome proliferator-activated receptor gamma partial agonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
In preclinical studies comparing T131 to Avandia, T131 demonstrated superior potency and an improved side effect profile. In these studies, T131 treatment did not result in fluid retention or cardiac hypertrophy. In Phase 1 studies with T131, all doses were well tolerated and no serious adverse events were observed.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- E7ILQ6U50J
- CAS number
- 315224-26-1
- InChI Key
- NMRWDFUZLLQSBN-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H12Cl4N2O3S/c22-13-5-6-20(16(23)8-13)31(28,29)27-14-9-17(24)21(18(25)10-14)30-15-7-12-3-1-2-4-19(12)26-11-15/h1-11,27H
- IUPAC Name
- 2,4-dichloro-N-[3,5-dichloro-4-(quinolin-3-yloxy)phenyl]benzene-1-sulfonamide
- SMILES
- ClC1=CC=C(C(Cl)=C1)S(=O)(=O)NC1=CC(Cl)=C(OC2=CN=C3C=CC=CC3=C2)C(Cl)=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 16145453
- PubChem Substance
- 175427019
- ChemSpider
- 8404988
- BindingDB
- 50428854
- ChEMBL
- CHEMBL1236924
- ZINC
- ZINC000006485945
- PDBe Ligand
- Z12
- PDB Entries
- 3fur
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Relapsing Remitting Multiple Sclerosis (RRMS) 1 2 Completed Treatment Type 2 Diabetes Mellitus 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 6.99e-05 mg/mL ALOGPS logP 6.43 ALOGPS logP 6.54 Chemaxon logS -6.9 ALOGPS pKa (Strongest Acidic) 7.11 Chemaxon pKa (Strongest Basic) 3.75 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 68.29 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 122.27 m3·mol-1 Chemaxon Polarizability 45.91 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.5124 Blood Brain Barrier - 0.8222 Caco-2 permeable - 0.7653 P-glycoprotein substrate Substrate 0.8349 P-glycoprotein inhibitor I Non-inhibitor 0.9228 P-glycoprotein inhibitor II Non-inhibitor 0.9804 Renal organic cation transporter Non-inhibitor 0.6511 CYP450 2C9 substrate Non-substrate 0.8205 CYP450 2D6 substrate Non-substrate 0.7884 CYP450 3A4 substrate Non-substrate 0.5857 CYP450 1A2 substrate Non-inhibitor 0.842 CYP450 2C9 inhibitor Non-inhibitor 0.8117 CYP450 2D6 inhibitor Non-inhibitor 0.8597 CYP450 2C19 inhibitor Non-inhibitor 0.7535 CYP450 3A4 inhibitor Non-inhibitor 0.8569 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9547 Ames test Non AMES toxic 0.6682 Carcinogenicity Non-carcinogens 0.8674 Biodegradation Not ready biodegradable 0.9136 Rat acute toxicity 2.6246 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.875 hERG inhibition (predictor II) Non-inhibitor 0.5253
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 210.13063 predictedDeepCCS 1.0 (2019) [M+H]+ 212.5262 predictedDeepCCS 1.0 (2019) [M+Na]+ 218.43872 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Partial agonist
- General Function
- Zinc ion binding
- Specific Function
- Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
- Gene Name
- PPARG
- Uniprot ID
- P37231
- Uniprot Name
- Peroxisome proliferator-activated receptor gamma
- Molecular Weight
- 57619.58 Da
Drug created at November 18, 2007 18:25 / Updated at June 12, 2020 16:52